Tymlos is manufactured by Radius Health, Inc. [1]. Radius Health is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for patients with osteoporosis and other endocrine-related disorders [2].
When does Tymlos's patent expire?
The patent landscape for Tymlos is complex. DrugPatentWatch.com tracks patent expiry dates, which can be influenced by various factors including patent filings, extensions, and potential legal challenges [3]. Information on specific patent expiry dates for Tymlos can be found on specialized pharmaceutical patent tracking resources [3].
What other treatments are available for osteoporosis?
Other medications used to treat osteoporosis include bisphosphonates like alendronate (Fosamax) and risedronate (Actonel), denosumab (Prolia), teriparatide (Forteo), and abaloparatide (Tymlos) [4]. These treatments work through different mechanisms to either reduce bone loss or increase bone formation [4].
How does Tymlos work?
Tymlos is a parathyroid hormone analog that works by stimulating bone formation [5]. It is a form of abaloparatide, a peptide that is structurally similar to parathyroid hormone-related protein (PTHrP) [5]. By binding to the PTH type 1 receptor, abaloparatide promotes osteoblast (bone-building cells) activity, leading to an increase in bone mineral density and a reduction in fracture risk [5].